#269 Osteoarthritis pain getting you down? Duloxetine
CLINICAL QUESTION
Do Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), specifically duloxetine, improve pain in patients with osteoarthritis?
BOTTOM LINE
Duloxetine can meaningfully reduce osteoarthritis pain scores (by at least 30%) for ~60% of patients compared to ~40% on placebo. An average pain of ~6 (scale 0-10) will be reduced by ~2.5 points, compared to 1.7 on placebo. Duloxetine adverse effects lead to withdrawal in 12% of patients versus 6% on placebo.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Six systematic reviews with 2-7 randomized controlled trials (RCTs) and 487-2102 patients.1-6 Duloxetine 60-120mg daily versus placebo, results statistically significant unless indicated.
- Proportion of patients attaining a meaningful pain reduction (generally ≥30% reduction in pain score):
- Systematic review (6 RCTs, 2060 patients)1 of hip or knee osteoarthritis, over 10-18 weeks: 64% taking duloxetine versus 43% taking placebo, number needed to treat (NNT)=5.
- Other systematic reviews found similar:3,5-6 NNT=6-9.
- One RCT (231 patients) randomized patients to 60mg or 120mg and found no difference.7
- Improvement in baseline pain scores (0-10 point scale, lower scores indicate less pain):
- Systematic review (5 RCTs, 2059 patients),5 patients started with an average score of 5.8: duloxetine improved pain 0.8 more than placebo, achieving a mean pain score of 3.3 versus 4.1 for placebo which is likely clinically meaningful.
- Another systematic review found similar.3
- Adverse events:
- Overall adverse events:4 55% versus 37% (placebo), number needed to harm (NNH)=6.
- Most common adverse events:4 gastrointestinal 36% versus 8% (placebo), (NNH=4).
- Specifically6 nausea (NNH 16), fatigue (NNH 17), constipation (NNH 19), erectile dysfunction (NNH 20), abdominal pain (NNH 34).
- Most common adverse events:4 gastrointestinal 36% versus 8% (placebo), (NNH=4).
- Withdrawal due to adverse events:4 12% versus 6% (placebo), NNH=17.
- Other systematic reviews found similar.1-6
- Limitations: all industry-funded studies.
- Overall adverse events:4 55% versus 37% (placebo), number needed to harm (NNH)=6.
- No RCTs looked at venlafaxine to treat osteoarthritis pain.
- Duloxetine is “conditionally recommended” by the Osteoarthritis Research Society International guidelines and by the American College of Rheumatology, however, tolerability needs to be considered.8-9
- A PEER Simplified Decision Aid on osteoarthritis can assist with patient informed decision making and is available online.10
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
These findings are in keeping with those found on the PEER Pain Calculator, which is a tool I use to increase patient buy-in with duloxetine.
Duloxetine fairly effective in reducing OA pain
nice
And may give mood benefit as a bonus.